The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

J. Iqbal, A. Ragone, J. Lubinski, Henry T. Lynch, P. Moller, P. Ghadirian, W. D. Foulkes, S. Armel, A. Eisen, S. L. Neuhausen, L. Senter, C. F. Singer, P. Ainsworth, C. Kim-Sing, N. Tung, E. Friedman, M. Llacuachaqui, S. Ping, S. A. Narod

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Background:Germline mutations in BRCA1 and BRCA2 predispose to pancreatic cancer. We estimated the incidence of pancreatic cancer in a cohort of female carriers of BRCA1 and BRCA2 mutation. We also estimated survival rates in pancreatic cancer cases from families with a BRCA mutation.Methods:We followed 5149 women with a mutation for new cases of pancreatic cancer. The standardised incidence ratios (SIR) for pancreatic cancer were calculated based on age group and country of residence. We also reviewed the pedigrees of 8140 pedigrees with a BRCA1 or a BRCA2 mutation for those with a case of pancreatic cancer. We recorded the year of diagnosis and the year of death for 351 identified cases.Results:Eight incident pancreatic cancer cases were identified among all mutation carriers. The SIR for BRCA1 carriers was 2.55 (95% CI=1.03-5.31, P=0.04) and for BRCA2 carriers was 2.13 (95% CI=0.36-7.03, P=0.3). The 5-year survival rate was 5% for cases from a BRCA1 family and 4% for cases from a BRCA2 family.Conclusion:The risk of pancreatic cancer is approximately doubled in female BRCA carriers. The poor survival in familial pancreatic cancer underscores the need for novel anti-tumoural strategies.

Original languageEnglish
Pages (from-to)2005-2009
Number of pages5
JournalBritish Journal of Cancer
Volume107
Issue number12
DOIs
StatePublished - Dec 4 2012
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Mutation
Incidence
Pedigree
Survival Rate
Germ-Line Mutation
Age Groups
Survival

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Iqbal, J., Ragone, A., Lubinski, J., Lynch, H. T., Moller, P., Ghadirian, P., ... Narod, S. A. (2012). The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 107(12), 2005-2009. https://doi.org/10.1038/bjc.2012.483

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. / Iqbal, J.; Ragone, A.; Lubinski, J.; Lynch, Henry T.; Moller, P.; Ghadirian, P.; Foulkes, W. D.; Armel, S.; Eisen, A.; Neuhausen, S. L.; Senter, L.; Singer, C. F.; Ainsworth, P.; Kim-Sing, C.; Tung, N.; Friedman, E.; Llacuachaqui, M.; Ping, S.; Narod, S. A.

In: British Journal of Cancer, Vol. 107, No. 12, 04.12.2012, p. 2005-2009.

Research output: Contribution to journalArticle

Iqbal, J, Ragone, A, Lubinski, J, Lynch, HT, Moller, P, Ghadirian, P, Foulkes, WD, Armel, S, Eisen, A, Neuhausen, SL, Senter, L, Singer, CF, Ainsworth, P, Kim-Sing, C, Tung, N, Friedman, E, Llacuachaqui, M, Ping, S & Narod, SA 2012, 'The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers', British Journal of Cancer, vol. 107, no. 12, pp. 2005-2009. https://doi.org/10.1038/bjc.2012.483
Iqbal, J. ; Ragone, A. ; Lubinski, J. ; Lynch, Henry T. ; Moller, P. ; Ghadirian, P. ; Foulkes, W. D. ; Armel, S. ; Eisen, A. ; Neuhausen, S. L. ; Senter, L. ; Singer, C. F. ; Ainsworth, P. ; Kim-Sing, C. ; Tung, N. ; Friedman, E. ; Llacuachaqui, M. ; Ping, S. ; Narod, S. A. / The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. In: British Journal of Cancer. 2012 ; Vol. 107, No. 12. pp. 2005-2009.
@article{b7371a137b0046678b25592fef74f376,
title = "The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers",
abstract = "Background:Germline mutations in BRCA1 and BRCA2 predispose to pancreatic cancer. We estimated the incidence of pancreatic cancer in a cohort of female carriers of BRCA1 and BRCA2 mutation. We also estimated survival rates in pancreatic cancer cases from families with a BRCA mutation.Methods:We followed 5149 women with a mutation for new cases of pancreatic cancer. The standardised incidence ratios (SIR) for pancreatic cancer were calculated based on age group and country of residence. We also reviewed the pedigrees of 8140 pedigrees with a BRCA1 or a BRCA2 mutation for those with a case of pancreatic cancer. We recorded the year of diagnosis and the year of death for 351 identified cases.Results:Eight incident pancreatic cancer cases were identified among all mutation carriers. The SIR for BRCA1 carriers was 2.55 (95{\%} CI=1.03-5.31, P=0.04) and for BRCA2 carriers was 2.13 (95{\%} CI=0.36-7.03, P=0.3). The 5-year survival rate was 5{\%} for cases from a BRCA1 family and 4{\%} for cases from a BRCA2 family.Conclusion:The risk of pancreatic cancer is approximately doubled in female BRCA carriers. The poor survival in familial pancreatic cancer underscores the need for novel anti-tumoural strategies.",
author = "J. Iqbal and A. Ragone and J. Lubinski and Lynch, {Henry T.} and P. Moller and P. Ghadirian and Foulkes, {W. D.} and S. Armel and A. Eisen and Neuhausen, {S. L.} and L. Senter and Singer, {C. F.} and P. Ainsworth and C. Kim-Sing and N. Tung and E. Friedman and M. Llacuachaqui and S. Ping and Narod, {S. A.}",
year = "2012",
month = "12",
day = "4",
doi = "10.1038/bjc.2012.483",
language = "English",
volume = "107",
pages = "2005--2009",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

AU - Iqbal, J.

AU - Ragone, A.

AU - Lubinski, J.

AU - Lynch, Henry T.

AU - Moller, P.

AU - Ghadirian, P.

AU - Foulkes, W. D.

AU - Armel, S.

AU - Eisen, A.

AU - Neuhausen, S. L.

AU - Senter, L.

AU - Singer, C. F.

AU - Ainsworth, P.

AU - Kim-Sing, C.

AU - Tung, N.

AU - Friedman, E.

AU - Llacuachaqui, M.

AU - Ping, S.

AU - Narod, S. A.

PY - 2012/12/4

Y1 - 2012/12/4

N2 - Background:Germline mutations in BRCA1 and BRCA2 predispose to pancreatic cancer. We estimated the incidence of pancreatic cancer in a cohort of female carriers of BRCA1 and BRCA2 mutation. We also estimated survival rates in pancreatic cancer cases from families with a BRCA mutation.Methods:We followed 5149 women with a mutation for new cases of pancreatic cancer. The standardised incidence ratios (SIR) for pancreatic cancer were calculated based on age group and country of residence. We also reviewed the pedigrees of 8140 pedigrees with a BRCA1 or a BRCA2 mutation for those with a case of pancreatic cancer. We recorded the year of diagnosis and the year of death for 351 identified cases.Results:Eight incident pancreatic cancer cases were identified among all mutation carriers. The SIR for BRCA1 carriers was 2.55 (95% CI=1.03-5.31, P=0.04) and for BRCA2 carriers was 2.13 (95% CI=0.36-7.03, P=0.3). The 5-year survival rate was 5% for cases from a BRCA1 family and 4% for cases from a BRCA2 family.Conclusion:The risk of pancreatic cancer is approximately doubled in female BRCA carriers. The poor survival in familial pancreatic cancer underscores the need for novel anti-tumoural strategies.

AB - Background:Germline mutations in BRCA1 and BRCA2 predispose to pancreatic cancer. We estimated the incidence of pancreatic cancer in a cohort of female carriers of BRCA1 and BRCA2 mutation. We also estimated survival rates in pancreatic cancer cases from families with a BRCA mutation.Methods:We followed 5149 women with a mutation for new cases of pancreatic cancer. The standardised incidence ratios (SIR) for pancreatic cancer were calculated based on age group and country of residence. We also reviewed the pedigrees of 8140 pedigrees with a BRCA1 or a BRCA2 mutation for those with a case of pancreatic cancer. We recorded the year of diagnosis and the year of death for 351 identified cases.Results:Eight incident pancreatic cancer cases were identified among all mutation carriers. The SIR for BRCA1 carriers was 2.55 (95% CI=1.03-5.31, P=0.04) and for BRCA2 carriers was 2.13 (95% CI=0.36-7.03, P=0.3). The 5-year survival rate was 5% for cases from a BRCA1 family and 4% for cases from a BRCA2 family.Conclusion:The risk of pancreatic cancer is approximately doubled in female BRCA carriers. The poor survival in familial pancreatic cancer underscores the need for novel anti-tumoural strategies.

UR - http://www.scopus.com/inward/record.url?scp=84870802792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870802792&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.483

DO - 10.1038/bjc.2012.483

M3 - Article

VL - 107

SP - 2005

EP - 2009

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -